Molecular and nanoengineering approaches towards activatable cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Cancer immunotherapy harnesses the immune system to combat cancer but faces challenges like low response rates and immune-related adverse events.
• Nanomedicines offer controlled delivery and modularity, presenting a promising avenue to overcome these limitations in cancer immunotherapy.
• Current immunotherapeutic strategies require optimization for enhanced safety and efficacy in clinical settings.

Purpose of the Study:

• To review the convergence of nanomedicine and immunotherapy, focusing on activatable nanoagents for cancer treatment.
• To explore molecular and nanoengineering strategies for developing stimuli-responsive immunotherapeutic nanoagents.
• To discuss the clinical translation prospects and challenges of activatable cancer immunotherapy.

Main Methods:

• Review of current literature on nanomedicine applications in cancer immunotherapy.
• Analysis of molecular and nanoengineering approaches for creating activatable nanoagents.
• Discussion of stimuli-responsive mechanisms for targeted immunotherapeutic action.

Main Results:

• Activatable nanoagents can be engineered to respond to internal or external stimuli for localized immune activation.
• These agents can reprogram the tumor microenvironment to enhance antitumor immunity.
• The stimuli-responsive nature of these nanomedicines has the potential to reduce systemic immune-related adverse events.

Conclusions:

• Activatable nanomedicines represent a significant advancement in cancer immunotherapy, offering targeted and controlled immune modulation.
• This approach holds promise for improving patient response rates and mitigating adverse events, facilitating clinical translation.
• Further research and development are crucial to address the challenges in the clinical application of these innovative nanoagents.